Patient recruitment for COVID-19 study completed

Dimerix (ASX:DXB) announced today that the CLARITY 2.0 led study of COVID-19 patients has concluded recruitment to allow this study to be analysed and reported.

DXB recruited 49 patients into the CLARITY 2.0 study and the safety and efficacy results of the clinical trial are currently being analysed and will be reported once available.

Now that recruitment has concluded, DXB can assess the current data for positive signs of proof of concept. If a positive signal is substantiated, DXB says it may then assess the next steps to progress towards the ultimate therapeutic outcome for these patients.

If DXB proves its CLARITY 2.0 treatment to be effective, we expect the treatment to be transferable to other patients with pneumonia and a wide range of respiratory diseases, not just those caused by COVID-19.

That would be a significant win for DXB and today’s announcement marks progress towards Objective #2 from our DXB Investment Memo.

What’s next for DXB? We are eagerly awaiting a patient recruitment update on what we view as the primary Phase 3 DXB study - the FSGS trial.